View in EDS HTML Full Text PDF Full Text

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.

Saved in:
Bibliographic Details
Title: Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Authors: Ostrowitzki S; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Bittner T; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc, South San Francisco, California., Sink KM; Genentech, Inc, South San Francisco, California., Mackey H; Genentech, Inc, South San Francisco, California., Rabe C; Genentech, Inc, South San Francisco, California., Honig LS; Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York., Cassetta E; Fatebenefratelli Foundation, Associazione Fatebenefratelli Per la Ricerca Division, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy., Woodward M; Austin Health Continuing Care Clinical Service Unit, Heidelberg, Germany.; University of Melbourne, Melbourne, Victoria, Australia., Boada M; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., van Dyck CH; Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, Connecticut., Grimmer T; Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany., Selkoe DJ; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Schneider A; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Blondeau K; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Hu N; Genentech, Inc, South San Francisco, California., Quartino A; Genentech, Inc, South San Francisco, California.; Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden., Clayton D; Genentech, Inc, South San Francisco, California., Dolton M; Roche Products Australia Pty Ltd, Sydney, New South Wales, Australia., Dang Y; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Sanofi Genzyme, Waltham, Massachusetts., Ostaszewski B; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Sanabria-Bohórquez SM; Genentech, Inc, South San Francisco, California., Rabbia M; Genentech, Inc, South San Francisco, California., Toth B; Genentech, Inc, South San Francisco, California., Eichenlaub U; Roche Diagnostics GmbH, Penzberg, Germany., Smith J; Roche Products Ltd, Welwyn Garden City, United Kingdom., Honigberg LA; Genentech, Inc, South San Francisco, California., Doody RS; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc, South San Francisco, California.
Source: JAMA neurology [JAMA Neurol] 2022 Nov 01; Vol. 79 (11), pp. 1113-1121.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36121669
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ostrowitzki+S%22">Ostrowitzki S</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bittner+T%22">Bittner T</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Sink+KM%22">Sink KM</searchLink>; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Mackey+H%22">Mackey H</searchLink>; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Rabe+C%22">Rabe C</searchLink>; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Honig+LS%22">Honig LS</searchLink>; Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York.<br /><searchLink fieldCode="AU" term="%22Cassetta+E%22">Cassetta E</searchLink>; Fatebenefratelli Foundation, Associazione Fatebenefratelli Per la Ricerca Division, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy.<br /><searchLink fieldCode="AU" term="%22Woodward+M%22">Woodward M</searchLink>; Austin Health Continuing Care Clinical Service Unit, Heidelberg, Germany.; University of Melbourne, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Boada+M%22">Boada M</searchLink>; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain.; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22van+Dyck+CH%22">van Dyck CH</searchLink>; Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Grimmer+T%22">Grimmer T</searchLink>; Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Selkoe+DJ%22">Selkoe DJ</searchLink>; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Schneider+A%22">Schneider A</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Blondeau+K%22">Blondeau K</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Hu+N%22">Hu N</searchLink>; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Quartino+A%22">Quartino A</searchLink>; Genentech, Inc, South San Francisco, California.; Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Clayton+D%22">Clayton D</searchLink>; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Dolton+M%22">Dolton M</searchLink>; Roche Products Australia Pty Ltd, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Dang+Y%22">Dang Y</searchLink>; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Sanofi Genzyme, Waltham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Ostaszewski+B%22">Ostaszewski B</searchLink>; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Sanabria-Bohórquez+SM%22">Sanabria-Bohórquez SM</searchLink>; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Rabbia+M%22">Rabbia M</searchLink>; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Toth+B%22">Toth B</searchLink>; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Eichenlaub+U%22">Eichenlaub U</searchLink>; Roche Diagnostics GmbH, Penzberg, Germany.<br /><searchLink fieldCode="AU" term="%22Smith+J%22">Smith J</searchLink>; Roche Products Ltd, Welwyn Garden City, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Honigberg+LA%22">Honigberg LA</searchLink>; Genentech, Inc, South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Doody+RS%22">Doody RS</searchLink>; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc, South San Francisco, California.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101589536%22">JAMA neurology</searchLink> [JAMA Neurol] 2022 Nov 01; Vol. 79 (11), pp. 1113-1121.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101589536 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2168-6157 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221686149%22">21686149 </searchLink><i>NLM ISO Abbreviation: </i>JAMA Neurol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36121669
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1001/jamaneurol.2022.2909
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1113
    Titles:
      – TitleFull: Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ostrowitzki S
      – PersonEntity:
          Name:
            NameFull: Bittner T
      – PersonEntity:
          Name:
            NameFull: Sink KM
      – PersonEntity:
          Name:
            NameFull: Mackey H
      – PersonEntity:
          Name:
            NameFull: Rabe C
      – PersonEntity:
          Name:
            NameFull: Honig LS
      – PersonEntity:
          Name:
            NameFull: Cassetta E
      – PersonEntity:
          Name:
            NameFull: Woodward M
      – PersonEntity:
          Name:
            NameFull: Boada M
      – PersonEntity:
          Name:
            NameFull: van Dyck CH
      – PersonEntity:
          Name:
            NameFull: Grimmer T
      – PersonEntity:
          Name:
            NameFull: Selkoe DJ
      – PersonEntity:
          Name:
            NameFull: Schneider A
      – PersonEntity:
          Name:
            NameFull: Blondeau K
      – PersonEntity:
          Name:
            NameFull: Hu N
      – PersonEntity:
          Name:
            NameFull: Quartino A
      – PersonEntity:
          Name:
            NameFull: Clayton D
      – PersonEntity:
          Name:
            NameFull: Dolton M
      – PersonEntity:
          Name:
            NameFull: Dang Y
      – PersonEntity:
          Name:
            NameFull: Ostaszewski B
      – PersonEntity:
          Name:
            NameFull: Sanabria-Bohórquez SM
      – PersonEntity:
          Name:
            NameFull: Rabbia M
      – PersonEntity:
          Name:
            NameFull: Toth B
      – PersonEntity:
          Name:
            NameFull: Eichenlaub U
      – PersonEntity:
          Name:
            NameFull: Smith J
      – PersonEntity:
          Name:
            NameFull: Honigberg LA
      – PersonEntity:
          Name:
            NameFull: Doody RS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2022 Nov 01
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2168-6157
          Numbering:
            – Type: volume
              Value: 79
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: JAMA neurology
              Type: main
ResultId 1